QQ客服 官方微博 反馈留言

	Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result
	Cai, Shaohang; Yu, Tao; Jiang, Yegui; Zhang, Yonghong; Lv, Fangfang; Peng, Jie*
刊名	Clinical and Experimental Medicine
	2016
卷号	16期号:3页码:429-436
关键词	Chronic hepatitis B High viral load Nucleos(t)ide analogs Virologic response
ISSN号	1591-8890
DOI	10.1007/s10238-015-0373-2
URL标识	查看原文
WOS记录号	WOS:000380668500022
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3318293
专题	中南大学
作者单位	1.[Peng, Jie 2.Cai, Shaohang 3.Yu, Tao] Southern Med Univ, Nanfang Hosp, Dept Infect Dis, Guangzhou 510515, Guangdong, Peoples R China.
推荐引用方式 GB/T 7714	Cai, Shaohang,Yu, Tao,Jiang, Yegui,et al. Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result[J]. Clinical and Experimental Medicine,2016,16(3):429-436.
APA	Cai, Shaohang,Yu, Tao,Jiang, Yegui,Zhang, Yonghong,Lv, Fangfang,&Peng, Jie*.(2016).Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result.Clinical and Experimental Medicine,16(3),429-436.
MLA	Cai, Shaohang,et al."Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result".Clinical and Experimental Medicine 16.3(2016):429-436.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。